Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CLS-12311 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
CLS-12311: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
EP-547 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
EP-547: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
EMP-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
EMP-01: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
PRT-811 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
PRT-811: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
SNB-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SNB-101: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
SER-287 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SER-287: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
KYN-5356 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
KYN-5356: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
CTX-471 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
CTX-471: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
OAT-889 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
OAT-889: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
S-337395 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
S-337395: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
IFM-2427 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
IFM-2427: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
BNZ-1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
BNZ-1: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.